Perilla frutescens extract ameliorates dss-induced colitis by suppressing proinflammatory cytokines and inducing Anti-Inflammatory cytokines

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 308, Issue 1, 2015, Pages G32-G41

  Urushima, Hayato ^a   Nishimura, Junichi ^a   Mizushima, Tsunekazu ^a   Hayashi, Noriyuki ^a   Maeda, Kazuhisa ^a   Ito, Toshinori ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Interleukin 17A; Perilla frutescens; Regulatory T cells; T helper 17; Tumor necrosis factor

Indexed keywords

ANTIINFLAMMATORY AGENT; APIGENIN; CYTOKINE; DEXTRAN SULFATE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; LUTEOLIN; MESSENGER RNA; PERILLA FRUTESCENS EXTRACT; PLANT EXTRACT; ROSMARINIC ACID; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTACOID; GASTROINTESTINAL AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; IN VITRO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PERILLA FRUTESCENS; PLANT LEAF; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; WEIGHT REDUCTION; ANIMAL; BLOOD; BODY WEIGHT; C57BL MOUSE; CHEMICALLY INDUCED; CHEMISTRY; COLON; DISEASE MODEL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; MEDICINAL PLANT; METABOLISM; PHYTOTHERAPY; TH17 CELL; TIME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BODY WEIGHT; COLITIS; COLON; CYTOKINES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; GASTROINTESTINAL AGENTS; INFLAMMATION MEDIATORS; MICE, INBRED C57BL; PERILLA FRUTESCENS; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; RNA, MESSENGER; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; TIME FACTORS;

EID: 84920075607     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00294.2014     Document Type: Article

References (50)

1. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8: 942–949, 2007.
2. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190: 995–1004, 1999.
3. Atarashi K, Nishimura J, Shima T, Umesaki Y, Yamamoto M, Onoue M, Yagita H, Ishii N, Evans R, Honda K, Takeda K. ATP drives lamina propria T(H)17 cell differentiation. Nature 455: 808–812, 2008.
4. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235–238, 2006.
5. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol 106: 674–684, 2011.
6. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, Plevy S. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 98: 1315–1324, 2003.
7. Cosmi L, De Palma R, Santarlasci V, Maggi L, Capone M, Frosali F, Rodolico G, Querci V, Abbate G, Angeli R, Berrino L, Fambrini M, Caproni M, Tonelli F, Lazzeri E, Parronchi P, Liotta F, Maggi E, Romagnani S, Annunziato F. Human interleukin 17-producing cells originate from a CD161_CD4_ T cell precursor. J Exp Med 205: 1903–1916, 2008.
8. Fale PL, Ascensao L, Serralheiro ML. Effect of luteolin and apigenin on rosmarinic acid bioavailability in Caco-2 cell monolayers. Food Function 4: 426–431, 2013.
9. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52: 65–70, 2003.
10. Ganjare AB, Nirmal SA, Patil AN. Use of apigenin from Cordia dichotoma in the treatment of colitis. Fitoterapia 82: 1052–1056, 2011.
11. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359: 1541–1549, 2002.
12. Holtta V, Klemetti P, Sipponen T, Westerholm-Ormio M, Kociubinski G, Salo H, Rasanen L, Kolho KL, Farkkila M, Savilahti E, Vaarala O. IL-23/IL-17 immunity as a hallmark of Crohn’s disease. Inflamm Bowel Dis 14: 1175–1184, 2008.
13. Honda G, Koezuka Y, Kamisako W, Tabata M. Isolation of sedative principles from Perilla frutescens. Chem Pharmaceut Bull 34: 1672–1677, 1986.
14. Hundorfean G, Neurath MF, Mudter J. Functional relevance of T helper 17 (Th17) cells and the IL-17 cytokine family in inflammatory bowel disease. Inflamm Bowel Dis 18: 180–186, 2012.
15. Hur SJ, Kang SH, Jung HS, Kim SC, Jeon HS, Kim IH, Lee JD. Review of natural products actions on cytokines in inflammatory bowel disease. Nutr Res 32: 801–816, 2012.
16. Iba Y, Sugimoto Y, Kamei C, Masukawa T. Possible role of mucosal mast cells in the recovery process of colitis induced by dextran sulfate sodium in rats. Int Immunopharmacol 3: 485–491, 2003.
17. Igarashi M, Miyazaki Y. A review on bioactivities of Perilla: progress in research on the functions of Perilla as medicine and food. Evidence-based Compl Alt Med: eCAM 2013: 925342, 2013.
18. Imaoka K, Inouye S, Takahashi T, Kojima Y. Effects of Perilla frutescens extract on anti-DNP IgE antibody production in mice. Allergy 42: 74–80, 1993.
19. Ishihara T, Okamoto I, Masaki N, Kohno K, Tanimoto T, Ikegami H, Kurimoto M. Inhibition of antigen-specific T helper type 2 responses by Perilla frutescens extract. Allergy 48: 443–450, 1999.
20. Jiang WL, Chen XG, Qu GW, Yue XD, Zhu HB, Tian JW, Fu FH. Rosmarinic acid protects against experimental sepsis by inhibiting proinflammatory factor release and ameliorating hemodynamics. Shock 32: 608–613, 2009.
21. Karrasch T, Kim JS, Jang BI, Jobin C. The flavonoid luteolin worsens chemical-induced colitis in NF-kappaB(EGFP) transgenic mice through blockade of NF-kappaB-dependent protective molecules. PloS one 2: 596, 2007.
22. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098–1104, 2001.
23. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4_CD25_ T regulatory cells. Nat Immunol 4: 337–342, 2003.
24. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 474: 307–317, 2011.
25. Koezuka Y, Honda G, Tabata M. An intestinal propulsion promoting substance from Perilla frutescens and its mechanism of action. Planta Med 51: 480–482, 1985.
26. Liang YC, Huang YT, Tsai SH, Lin-Shiau SY, Chen CF, Lin JK. Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis 20: 1945–1952, 1999.
27. Maeda S, Hsu LC, Liu H, Bankston LA, Iimura M, Kagnoff MF, Eckmann L, Karin M. Nod2 mutation in Crohn’s disease potentiates NF-kappaB activity and IL-1beta processing. Science 307: 734–738, 2005.
28. Makino T, Ito M, Kiuchiu F, Ono T, Muso E, Honda G. Inhibitory effect of decoction of Perilla frutescens on cultured murine mesangial cell proliferation and quantitative analysis of its active constituents. Planta Med 67: 24–28, 2001.
29. Makino T, Ono T, Muso E, Honda G, Sasayama S. Suppressive effects of Perilla frutescens on spontaneous IgA nephropathy in ddY mice. Nephron 83: 40–46, 1999.
30. Mangan PR, Harrington LE, O’Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441: 231–234, 2006.
31. Mizushima T, Ito T, Kishi D, Kai Y, Tamagawa H, Nezu R, Kiyono H, Matsuda H. Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis. Inflamm Bowel Dis 10: 182–192, 2004.
32. Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin- 10 and the interleukin-10 receptor. Ann Rev Immunol 19: 683–765, 2001.
33. Nakamura M, Saito H, Kasanuki J, Tamura Y, Yoshida S. Cytokine production in patients with inflammatory bowel disease. Gut 33: 933–937, 1992.
34. Nicholas C, Batra S, Vargo MA, Voss OH, Gavrilin MA, Wewers MD, Guttridge DC, Grotewold E, Doseff AI. Apigenin blocks lipopolysaccharide- induced lethality in vivo and proinflammatory cytokines expression by inactivating NF-kappaB through the suppression of p65 phosphorylation. J Immunol 179: 7121–7127, 2007.
35. Nishitani Y, Yamamoto K, Yoshida M, Azuma T, Kanazawa K, Hashimoto T, Mizuno M. Intestinal anti-inflammatory activity of luteolin: role of the aglycone in NF-kappaB inactivation in macrophages co-cultured with intestinal epithelial cells. BioFactors 39: 522–533, 2013.
36. Park CM, Jin KS, Lee YW, Song YS. Luteolin and chicoric acid synergistically inhibited inflammatory responses via inactivation of PI3KAkt pathway and impairment of NF-kappaB translocation in LPS stimulated RAW 264.7 cells. Eur J Pharmacol 660: 454–459, 2011.
37. Podolsky DK. Inflammatory bowel disease. N Engl J Med 347: 417–429, 2002.
38. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(_)CD4(_) regulatory cells that control intestinal inflammation. J Exp Med 192: 295–302, 2000.
39. Rennick DM, Fort MM, Davidson NJ. Studies with IL-10-/- mice: an overview. J Leukocyte Biol 61: 389–396, 1997.
40. Ruiz PA, Haller D. Functional diversity of flavonoids in the inhibition of the proinflammatory NF-kappaB, IRF, and Akt signaling pathways in murine intestinal epithelial cells. J Nutr 136: 664–671, 2006.
41. Sanada Y, Mizushima T, Kai Y, Nishimura J, Hagiya H, Kurata H, Mizuno H, Uejima E, Ito T. Therapeutic effects of novel sphingosine- 1-phosphate receptor agonist W-061 in murine DSS colitis. PloS one 6: e23933, 2011.
42. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350: 876–885, 2004.
43. Shin TY, Kim SH, Kim SH, Kim YK, Park HJ, Chae BS, Jung HJ, Kim HM. Inhibitory effect of mast cell-mediated immediate-type allergic reactions in rats by Perilla frutescens. Immunopharmacol Immunotoxicol 22: 489–500, 2000.
44. Song J, Matsuda C, Kai Y, Nishida T, Nakajima K, Mizushima T, Kinoshita M, Yasue T, Sawa Y, Ito T. A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice. J Pharmacol Exp Ther 324: 276–283, 2008.
45. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 140: 1756–1767, 2011.
46. Ueda H, Yamazaki M. Anti-inflammatory and anti-allergic actions by oral administration of a perilla leaf extract in mice. Biosci Biotechnol Biochem 65: 1673–1675, 2001.
47. Ueda H, Yamazaki M. Inhibition of tumor necrosis factor-alpha production by orally administering a perilla leaf extract. Biosc Biotechnol Biochem 61: 1292–1295, 1997.
48. Watanabe K, Matsuda M, Furuhashi S, Kimura T, Matsunaga T, Yamamoto I. Skin reaction induced by aldehydes for food flavoring agents. J Health Sci 47: 327–329, 2001.
49. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 106: 685–698, 2011.
50. Yu QT, Saruta M, Avanesyan A, Fleshner PR, Banham AH, Papadakis KA. Expression and functional characterization of FOXP3_ CD4_ regulatory T cells in ulcerative colitis. Inflamm Bowel Dis 13: 191–199, 2007.